Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control (NQF 0075)

EMeasure Name	Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control	**EMeasure Id**	Pending
Version Number	1	**Set Id**	Pending
Available Date	No information	**Measurement Period**	January 1, 20xx through December 31, 20xx
Measure Steward	National Committee for Quality Assurance		
Endorsed by	National Quality Forum		
Description	The percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1–November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and who had a complete lipid profile performed during the measurement year and whose LDL-C was <100 mg/dL.		
Measure scoring	Proportion		
Measure type	Process		
Rationale	This measure evaluates the percentage of patients in a specific age demographic who had a diagnosis of IVD and demonstrated adequate LDL cholesterol management. IVD and related conditions had an estimated cost burden of $393.5 billion in 2005 (AHA 2005). From 1988–1994 and from 1999–2002, adults 20 and older demonstrated lower age-adjusted total serum cholesterol levels (Carroll 2005), but there is significant room for improvement. Literature reviews and clinical guidelines advise that individuals with coronary artery disease can reduce their risk of subsequent morbidity and premature mortality by managing their cholesterol level through limitations on dietary fat and cholesterol, or in certain cases, through cholesterol lowering medications. A 10% decline in total cholesterol levels (population-wide) can result in a nearly 30% reduction in the incidence of CHD (CDC 2000). This measure facilitates the long-term management of LDL cholesterol levels for patients with IVD.		
Clinical Recommendation Statement	Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). (2001) AND Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines (2004): In high-risk persons, the recommended LDL-C goal is <100 mg/dL. • An LDL-C goal of <70 mg/dL is a therapeutic option on the basis of available clinical trial evidence, especially for patients at very high risk. • If LDL-C is >100 mg/dL, an LDL-lowering drug is indicated simultaneously with lifestyle changes. • If baseline LDL-C is <100 mg/dL, institution of an LDL-lowering drug to achieve an LDL-C level <70 mg/dL is a therapeutic option on the basis of available clinical trial evidence. • If a high-risk person has high triglycerides or low HDL-C, consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering		

	drug. When triglycerides are >200 mg/dL, non-HDL-C is a secondary target of therapy, with a goal 30 mg/dL higher than the identified LDL-C goal.
References	National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda (MD): U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung and Blood Institute; 2001 May.
Definitions	

Table of Contents

Please refer to the spreadsheet for this measure for detail regarding data criteria and code lists.

Population criteria

- **Initial Patient Population** =
    - AND: "Patient characteristic: birth date" (age) > = 17 years to capture all patients who will reach the age of 18 and older during the "measurement period";
- **Denominator** =
    - OR: "Procedure performed: PTCA" >=14 months and <= 24 months before or simultaneously to "measurement end date";
    - OR:
        - AND: "Encounter: encounter acute inpt" >=14 months and <= 24 months before or simultaneously to "measurement end date";
        - AND: "Diagnosis active: acute myocardial infarction" during "Encounter: encounter acute inpt";
    - OR:
        - AND: "Encounter: encounter acute inpt" >=14 months and <= 24 before or simultaneously to"measurement end date";
        - AND: "Procedure performed: CABG" >=14 months and <= 24 months before or simultaneously to "measurement end date";
    - OR:
        - AND: "Encounter: encounter acute inpt and outpt" <=2 years before or simultaneously to "measurement end date";
        - AND: "Diagnosis active: ischemic vascular disease" during "encounter: encounter acute inpt and outpt";
- **Numerator 1**=

- OR: “Laboratory test performed: LDL test”;
- OR:
  - AND: “Laboratory test performed: High Density Lipoprotein (HDL)”;
  - AND: “Laboratory test performed: total cholesterol”;
  - AND: “Laboratory test performed: triglycerides”;

- **Numerator 2**=
  - OR: “Laboratory test performed: LDL test”, value < 100 mg/dL;
  - OR:
    - AND: “Laboratory test performed: triglycerides”, value < 400 mg/dL;
    - AND: (“Laboratory test performed: total Cholesterol”, value
      – “Laboratory test performed: High Density Lipoprotein (HDL)”, value
      – “Laboratory test performed: triglycerides”, value/5)
      < 100 mg/dL;
- **Exclusions** =
  - None;

<u>Data criteria</u> (QDS Data Elements)

- **Initial Patient Population =**
  - “Patient characteristic: birth date” using “birth date code list” before the beginning of the “measurement period”;
- **Denominator** =
  - “Encounter: Encounter acute inpt” using “encounter acute inpt code list” before the “measurement end date”;
  - “Encounter: Encounter acute inpt and outpt” using “encounter acute inpt and outpt code list grouping” before “measurement end date”;
  - “Diagnosis active: acute myocardial infarction” using “acute myocardial infarction code list grouping” before the “measurement end date”;
  - “Diagnosis active: ischemic vascular disease” using “ischemic vascular disease code list grouping” before the “measurement end date”;
  - “Procedure performed: PTCA” (Percutaneous Transluminal Cardiac Angioplasty) using “PTCA code list grouping” before the “measurement end date”;
  - “Procedure performed: CABG” (Coronary Artery Bypass Graft) using “CABG code list grouping” before the “measurement end date”;
- **Numerator** =
  - “Laboratory test performed: High Density Lipoprotein (HDL)” using “High Density Lipoprotein (HDL) code list grouping” during the “measurement period”;
  - “Laboratory test performed: LDL test” using “LDL test code list grouping” during the “measurement period”;
  - “Laboratory test performed: total cholesterol” using “total cholesterol code list grouping” during the “measurement period”;
  - “Laboratory test performed: triglycerides” using “triglycerides code list grouping” during the “measurement period”;

- **Exclusions =**
    - None;

Summary calculation

Calculation is generic to all measures:

- Calculate the final denominator by adding all that meet denominator criteria.
- Subtract from the final denominator all that do not meet numerator criteria yet also meet exclusion criteria. Note some measures do not have exclusion criteria.
- The performance calculation is the number meeting numerator criteria divided by the final denominator.
- For measures with multiple patient populations, repeat this process for each patient population and report each result separately.
- For measures with multiple numerators, calculate each numerator separately within each population using the paired exclusion.

Measure set	CLINICAL QUALITY MEASURE SET 2011-2012